ArticleiScience2022
ACE2-IgG1 fusions with improved
Article in iScience, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 48 citations in OpenAlex.
- Development of ACE2-tropic-betacoronavirus therapeutics for future pandemic preparedness.Nature communications · 2025Article
- Development of a trispecific fusion protein based on angiotensin-converting enzyme 2, glycoprotein 130, and tumor necrosis factor receptor 2 as a promising therapeutic for COVID-19.Molecular biomedicine · 2025Article
- Rational design of a covalent ACE2 decoy receptor that broadly neutralizes SARS-CoV-2 variants.Protein science : a publication of the Protein Society · 2025Article
- Article
- Disulfide Bond Engineering of Soluble ACE2 for Thermal Stability Enhancement.International journal of molecular sciences · 2024Article
- Modulation of the pharmacokinetics of soluble ACE2 decoy receptors through glycosylation.Molecular therapy. Methods & clinical development · 2024Article
- Engineering a "muco-trapping" ACE2-immunoglobulin hybrid with picomolar affinity as an inhaled, pan-variant immunotherapy for COVID-19.Bioengineering & translational medicine · 2024Article
- Role of the RAAS in mediating the pathophysiology of COVID-19.Pharmacological reports : PR · 2024Review
- Altered COVID-19 immunity in children with asthma by atopic status.The journal of allergy and clinical immunology. Global · 2024Article
- SARS-CoV-2 Omicron: Viral Evolution, Immune Evasion, and Alternative Durable Therapeutic Strategies.Viruses · 2024Review
- Article
- Utilizing noncatalytic ACE2 protein mutant as a competitive inhibitor to treat SARS-CoV-2 infection.Frontiers in immunology · 2024Article
- COVID-19 and influenza infections mediate distinct pulmonary cellular and transcriptomic changes.Communications biology · 2023Article
- Comparison of SARS-CoV-2 entry inhibitors based on ACE2 receptor or engineered Spike-binding peptides.Journal of virology · 2023Article
- A computationally designed ACE2 decoy has broad efficacy against SARS-CoV-2 omicron variants and related viruses in vitro and in vivo.Communications biology · 2023Article
- Advances in developing ACE2 derivatives against SARS-CoV-2.The Lancet. Microbe · 2023Review
- Bivalent intra-spike binding provides durability against emergent Omicron lineages: Results from a global consortium.Cell reports · 2023Article
- Review
- Review
- Multivalent ACE2 engineering-A promising pathway for advanced coronavirus nanomedicine development.Nano today · 2022Review
Corrections and comments
- Update of
Authors and funding
19 authors at 5 institutions in 1 country.
Funding
Abstract
SARS-CoV-2, the etiologic agent of COVID-19, uses ACE2 as a cell entry receptor. Soluble ACE2 has been shown to have neutralizing antiviral activity but has a short half-life and no active transport mechanism from the circulation into the alveolar spaces of the lung. To overcome this, we constructed an ACE2-human IgG1 fusion protein with mutations in the catalytic domain of ACE2. A mutation in the catalytic domain of ACE2, MDR504, significantly increased binding to SARS-CoV-2 spike protein, as well as to a spike variant,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.